236 related articles for article (PubMed ID: 26375053)
1. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells.
Wu H; Wang A; Zhang W; Wang B; Chen C; Wang W; Hu C; Ye Z; Zhao Z; Wang L; Li X; Yu K; Liu J; Wu J; Yan XE; Zhao P; Wang J; Wang C; Weisberg EL; Gray NS; Yun CH; Liu J; Chen L; Liu Q
Oncotarget; 2015 Oct; 6(31):31313-22. PubMed ID: 26375053
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode.
Hu C; Wang A; Wu H; Qi Z; Li X; Yan XE; Chen C; Yu K; Zou F; Wang W; Wang W; Wu J; Liu J; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
Oncotarget; 2017 Mar; 8(11):18359-18372. PubMed ID: 28407693
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Walter AO; Sjin RT; Haringsma HJ; Ohashi K; Sun J; Lee K; Dubrovskiy A; Labenski M; Zhu Z; Wang Z; Sheets M; St Martin T; Karp R; van Kalken D; Chaturvedi P; Niu D; Nacht M; Petter RC; Westlin W; Lin K; Jaw-Tsai S; Raponi M; Van Dyke T; Etter J; Weaver Z; Pao W; Singh J; Simmons AD; Harding TC; Allen A
Cancer Discov; 2013 Dec; 3(12):1404-15. PubMed ID: 24065731
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation.
Wang A; Yan XE; Wu H; Wang W; Hu C; Chen C; Zhao Z; Zhao P; Li X; Wang L; Wang B; Ye Z; Wang J; Wang C; Zhang W; Gray NS; Weisberg EL; Chen L; Liu J; Yun CH; Liu Q
Oncotarget; 2016 Oct; 7(43):69760-69769. PubMed ID: 27626175
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
6. Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma.
Hu J; Zhang H; Cao M; Wang L; Wu S; Fang B
Mol Cancer Ther; 2018 Oct; 17(10):2156-2163. PubMed ID: 30065099
[TBL] [Abstract][Full Text] [Related]
7. Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Gao W; Wang M; Wang L; Lu H; Wu S; Dai B; Ou Z; Zhang L; Heymach JV; Gold KA; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214559
[TBL] [Abstract][Full Text] [Related]
8. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.
Wang A; Li X; Wu H; Zou F; Yan XE; Chen C; Hu C; Yu K; Wang W; Zhao P; Wu J; Qi Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Yun CH; Liu J; Liu Q
J Med Chem; 2017 Apr; 60(7):2944-2962. PubMed ID: 28282122
[TBL] [Abstract][Full Text] [Related]
9. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
10. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.
Zhang T; Qu R; Chan S; Lai M; Tong L; Feng F; Chen H; Song T; Song P; Bai G; Liu Y; Wang Y; Li Y; Su Y; Shen Y; Sun Y; Chen Y; Geng M; Ding K; Ding J; Xie H
Mol Cancer; 2020 May; 19(1):90. PubMed ID: 32404161
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
[TBL] [Abstract][Full Text] [Related]
13. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
14. Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S.
Wang TH; Leu YL; Chen CC; Li HJ; Yang SC; Huang KY; Chen CY
Phytother Res; 2022 May; 36(5):2116-2126. PubMed ID: 35229911
[TBL] [Abstract][Full Text] [Related]
15. Ursolic acid promotes apoptosis and mediates transcriptional suppression of CT45A2 gene expression in non-small-cell lung carcinoma harbouring EGFR T790M mutations.
Yang K; Chen Y; Zhou J; Ma L; Shan Y; Cheng X; Wang Y; Zhang Z; Ji X; Chen L; Dai H; Zhu B; Li C; Tao Z; Hu X; Yin W
Br J Pharmacol; 2019 Dec; 176(24):4609-4624. PubMed ID: 31322286
[TBL] [Abstract][Full Text] [Related]
16. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
[TBL] [Abstract][Full Text] [Related]
18. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
[TBL] [Abstract][Full Text] [Related]
19. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
20. Noncovalent wild-type-sparing inhibitors of EGFR T790M.
Lee HJ; Schaefer G; Heffron TP; Shao L; Ye X; Sideris S; Malek S; Chan E; Merchant M; La H; Ubhayakar S; Yauch RL; Pirazzoli V; Politi K; Settleman J
Cancer Discov; 2013 Feb; 3(2):168-81. PubMed ID: 23229345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]